12-dose Isoniazid/Rifapentine Regimen for Latent TB Infection Treatment
This fact sheet provides an overview of the 12-dose regimen for treating latent TB infection.
This fact sheet provides an overview of the 12-dose regimen for treating latent TB infection.
The website contains the history of World TB Day and multiple resources, including web graphics, that can be used in social media updates, websites, and presentations. This website also allows TB organizations to share their World TB Day 2017 activities.The 2017 US World TB Day theme is "Unite to End TB."
These modules are designed for health care workers and provide TB programmatic information. Module 6 provides information on managing patients and improving adherence. Module 8 provides information on conducting TB contact investigations.
This fact sheet provides an overview of how nurses help TB patients.
This guide provides an epidemiologic profile of TB in health care workers, as well as barriers in policy and practice, such as inadequate implementation of infection control.
This webinar provides an overview of the 2016 ATS/CDC/IDSA Treatment of Drug Susceptible Tuberculosis Guidelines and practical tips for implementation. Case studies are also presented.
This guide provides an overview of TB diagnostic tools and suggests recommendations for how activists and clinicians can contribute to improved TB diagnosis.
This document provides recommendations on the use chest radiography in TB detection. Specifically, the document provides information on chest radiography as a triage tool, diagnostic aid, and a screening tool. Additionally, quality assurance, safety, strategic planning, and technological developments are discussed.
The purpose of this toolkit is to assist TB programs in developing and implementing a TB eDOT program. Because eDOT programs can be very diverse to accommodate individual TB program needs, this toolkit provides general information that can be tailored to fit program needs.
The goal of this document is to provide practical answers to ethical questions in regard to the End TB Strategy.